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Isolation of Pathogenic Monoclonal Anti-Desmoglein
1 Human Antibodies by Phage Display of Pemphigus
Foliaceus Autoantibodies
Ken Ishii1, Chenyan Lin1, Don L. Siegel2 and John R. Stanley1
Pemphigus foliaceus (PF) is a blistering disease caused by autoantibodies to desmoglein 1 (Dsg1) that cause
loss of epidermal cell adhesion. To better understand PF pathophysiology, we used phage display to isolate anti-
Dsg1 mAbs as single-chain variable fragments (scFvs) from a PF patient. Initial panning of the library isolated
only non-pathogenic scFvs. We then used these scFvs to block non-pathogenic epitopes and were able to
isolate two unique scFvs, each of which caused typical PF blisters in mice or human epidermis models, showing
that a single mAb can disrupt Dsg1 function to cause disease. Both pathogenic scFvs bound conformational
epitopes in the N terminus of Dsg1. Other PF sera showed a major antibody response against the same or
nearby epitopes defined by these pathogenic scFvs. Finally, we showed restriction of the heavy-chain gene
usage of all anti-Dsg1 clones to only five genes, which determined their immunological properties despite
promiscuous light-chain gene usage. These mAbs will be useful for studying Dsg1 function and mechanisms
of blister formation in PF and for developing targeted therapies and tools to monitor disease activity.
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INTRODUCTION
Pemphigus foliaceus (PF) is a tissue-specific autoimmune
disease in which antibodies against the keratinocyte cell
surface cause skin blisters (Stanley and Amagai, 2006). These
blisters are due to loss of cell adhesion in the superficial living
epidermis (that is the granular layer), as shown by the
diagnostic histology from biopsies of the skin lesions of
these patients. The autoantibodies in this disease were first
detected by direct immunofluorescence in patients’ skin and
by indirect immunofluorescence in their sera. Subse-
quently, it was shown that antibodies in these patients bind
desmoglein 1 (Dsg1) (Koulu et al., 1984; Eyre and Stanley,
1987), a desmosomal cadherin found predominantly in the
superficial layers of stratified squamous epithelia. Desmo-
gleins are believed to function as cell–cell adhesion molecules
which, in epidermis, maintain its integrity. Polyclonal anti-
Dsg1 antibodies from PF patients have been shown to be
pathogenic in organ culture of normal human skin and by
passive transfer to neonatal mice, which result in blisters
with the typical histology of PF from loss of cell–cell adhesion
(Hashimoto et al., 1983; Roscoe et al., 1985; Rock et al., 1989).
Some patients with PF also have anti-Dsg4 antibodies (Kljuic
et al., 2003; Nagasaka et al., 2004). Dsg4, similar to Dsg1,
is found in the superficial epidermis (Bazzi et al., 2006).
However, recent studies in which anti-Dsg4 activity is adsorbed
out of PF sera suggest that the anti-Dsg4 activity is not necessary
for disease activity of such sera (Nagasaka et al., 2004).
To date, studies of the pathophysiology of anti-Dsg1
antibodies have been performed with polyclonal antibodies
from PF patients’ sera. Such studies have shown that in most
patients, the predominant antibody response is directed
against the N-terminal 161 amino acids of the 496 amino
acids in the extracellular domain of Dsg1 and that such
antibodies against the N terminus, where the transadhesion
binding site is located, are necessary for pathogenicity
(Sekiguchi et al., 2001). Furthermore, in the preclinical phase
of fogo selvagem, a form of endemic PF in Brazil, patients
develop IgG1 antibodies against the C terminus of the
extracellular domain of Dsg1. In clinically affected patients,
the antibody response switches to an IgG4 antibody against
the N terminus of Dsg1 (Aoki et al., 2004). The switch from
an IgG1 to an IgG4 response probably indicates a maturation
of the immune response. This switch does not implicate the
Fc region of IgG as necessary for disease because neither
the effector region of IgG nor crosslinking by IgG is necessary
for these PF antibodies to cause blisters. The latter conclusion
comes from studies that show that PF Fab’ monovalent
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fragments alone are capable of causing typical disease in
neonatal mice (Rock et al., 1990). In summary, these studies
have been interpreted to suggest that antibodies are needed
against the presumed N-terminal adhesive interface of
Dsg1 to cause loss of cell adhesion.
The importance of targeting the N terminus of desmogleins
to cause blister formation has also been demonstrated in
studies of pemphigus vulgaris (PV), in which autoantibodies
target Dsg3 and cause blisters deep in the epidermis. In a
study with xenoantibodies against human Dsg3, made in a
mouse, one anti-Dsg3 mAb that causes typical PV blisters
targeted the adhesive interface of Dsg3 (Tsunoda et al.,
2003). In addition, a human mAb cloned by phage display
from a PV patient, which causes typical PV lesions in a
mouse, is directed against the N-terminal 162 amino acids in
mouse Dsg3 (Payne et al., 2005).
The study of PF serum-derived polyclonal antibodies has
limitations for addressing many of the remaining questions
regarding the pathophysiology of the autoantibodies in this
disease. For example, are antibodies directed against the
N terminus of Dsg1 both necessary and sufficient for disease?
If so, can a single monoclonal, monovalent antibody, without
the effector region of IgG, cause disease or are antibodies
against multiple epitopes within this region necessary? If an
antibody against a single pathogenic epitope is capable of
causing disease, is that epitope also present in Dsg4? Do
various PF sera have antibodies against the same pathogenic
epitope? Finally, to consider the feasibility of developing
specific therapy targeted to pathogenic autoantibodies, it is
necessary to determine the genetic diversity of PF antibodies
and whether specific antibody genes are preferentially used
to produce them.
To address these questions, we used an antibody phage
display library panning technique to clone monoclonal anti-
Dsg1 single-chain variable fragment (scFv) antibodies from
a PF patient. Representative initial clones isolated from
the library by routine selection on Dsg1 were not pathogenic.
To capture pathogenic monoclonal scFv from this library, we
employed a non-pathogenic epitope-blocking approach. By
panning the library against Dsg1 in the presence of previously
isolated non-pathogenic scFvs, we isolated two unique clones
of anti-Dsg1 scFv that were pathogenic in mouse and human
skin. These human pathogenic mAbs did not crossreact
with Dsg4. Binding competition experiments between these
recombinant anti-Dsg1 scFvs and multiple PF patients’ sera
demonstrated that PF patients show a major antibody response
against the same or closely related epitopes, as those defined
by the pathogenic scFvs. Genetic, functional, and immuno-
logical characterization of all pathogenic and non-pathogenic
antibodies isolated from the PF scFv library showed that
their heavy-chain gene usage was very restricted, that their
immunologic properties correlated with antibody heavy-chain
gene usage, and that, although the light-chain gene usage
was more promiscuous, it was nevertheless restricted to a
small group of 18 light-chain genes.
These data also show that a single monoclonal human
antibody can disrupt the biological adhesion function of Dsg1
and cause the pathology characteristic of PF.
RESULTS
Isolation of non-pathogenic anti-Dsg1 scFvs from a PF patient
Peripheral blood lymphocytes from a patient with active
PF were used to construct a library in which each phage
particle displays an scFv antibody fragment on its surface
and contains the cDNA encoding the heavy and light-chain
variable regions for that particular scFv within. The library
was screened by multiple rounds of panning on immobilized,
baculovirus-produced Dsg1 using standard ELISA plate
panning methods (Barbas III et al., 2001). From this first
screening, we isolated 25 unique clones based on their
heavy and light-chain nucleotide sequences. All these clones
were derived from only two heavy-chain genes (VH1-18 and
VH3-09) but used multiple light-chain genes. Representative
antibodies using these heavy-chain genes were non-
pathogenic in mice and human organ culture (see below).
In order to try to increase the diversity of selected clones to
find pathogenic antibodies, we remade the library and tested
it again by panning on baculovirus-produced Dsg1 ELISA
plates. In this second panning, we found another 30 unique
clones, but again all but one used the VH1-18 and VH3-09
heavy-chain genes. In this panning, we found one additional
clone that uses the VH1-08 heavy-chain gene (1-08/O12O2),
but this clone was also non-pathogenic.
To address the possibility that the Dsg1 used in these initial
rounds of selection might lack pathogenic epitopes either
because it was produced in baculovirus or because critical
epitopes were blocked due to ELISA plate adsorption artifacts,
the phage library was panned in solution on mammalian-
produced Dsg1 using a magnetic bead approach. However,
the clones isolated using this panning method with the
alternative form of Dsg1 yielded scFv clones that were again
encoded by non-pathogenic VH1-18 and VH3-09 heavy-
chain genes.
Table 1 shows the isolated clones and their nomenclature.
(The table only lists clones with unique VDJ regions and light
chains, but does not list clones that differed only by somatic
mutations.)
Isolation of pathogenic anti-Dsg1 scFvs using a non-pathogenic
epitope-blocking approach
Given that the use of conventional ELISA plate and
in-solution antibody phage library selections yielded only
clones of antibodies that were either not pathogenic by direct
testing or unlikely to be pathogenic due to their immunologic
properties (that is shared heavy-chain usage, binding only to
denatured antigen, lack of binding to the cell surface of
keratinocytes; see below), we speculated that pathogenic
clones, if present in the library, may be there in amounts
too low, relative to non-pathogenic antibodies, to easily
isolate. We therefore designed a panning strategy to target
the isolation of such putative low-abundant clones by
blocking non-pathogenic epitopes with a set of previously
isolated non-pathogenic clones. To accomplish this, soluble
scFvs were expressed from representative clones utilizing
heavy chains encoded by VH1-18 (1-18/L1, 1-18/L12) and
VH3-09 (3-093/O12O2, 3-094/O18O8). By using this ‘‘non-
pathogenic epitope blocking’’ approach, we isolated five
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additional unique clones that were pathogenic (see below)
and were encoded by heavy-chain genes not previously seen
in our set of non-pathogenic anti-Dsg1 antibodies (VH3-07
and VH3-30) (see Table 1).
Immunochemical properties of the anti-Dsg1 scFv are
associated with their heavy-chain gene usage
ELISA analysis. Representative soluble scFvs were tested for
binding to Dsg1 (Figure 1) and Dsg3 by ELISA. All scFvs
bound Dsg1, as expected, and did not bind Dsg3, except
for two 3-07/1e clones (differed from each other only in
their light-chain VJ recombination) that showed weak binding
to Dsg3 at very high concentrations (data not shown).
Six VH1-18 clones bound strongly by ELISA to Dsg1, giving
an optical density (OD)450¼1 at concentrations from 0.4 to
2.8 ngml1 (two clones shown in Figure 1, light green lines).
VH3-09 clones also showed good binding to Dsg1; 9 of 12
clones tested gave OD450¼1 at 0.5–20 ngml1 (dark green
Table 1. Anti-Dsg1 clones representing each unique heavy chain (VDJ) and their associated light-chain genes
VH gene
Unique VDJ
region1 D gene J gene VL gene Name of clone
IIF
Dsg1
IB
Dsg4
binding Pathogenicity
Dsg1
epitope
Human
skin
Mouse
skin
VH1
VH1-18 VDJ1 D3-10/DXP’1 JH4b B3 1-18/B3 + +
L8 1-18/L8 +  +
L1 1-18/L1 +  +  2 164-401
L12 1-18/L12 + Weak + +   164-401
L2 1-18/L2
LFVK431 1-18/LFVK431 + +
VH1-08 VDJ2 D3-3/DXP4 JH6b O12/O2 1-08/O12O2 + +  +  1-161
VH3
VH3-09 VDJ3 D2-2 JH6b O12/O2 3-093/O12O2 Weak+3 Weak+  
O18/O8 3-093/O18O8 
L11 3-093/L11
A30 3-093/A30
1c 3-093/1c
1e 3-093/1e
1g 3-093/1g
6a 3-093/6a
VDJ4 D3-3/DXP4 JH3a O18/O8 3-094/O18O8 4 Weak+  +  1-161
VDJ5 O18/O8 3-095/O18O8 + +   1-161
L11 3-095/L11
VDJ6 L12 3-096/L12 
O18/O8 3-096/O18O8 Weak +
1c 3-096/1c
VDJ7 D3-3/DXP4 JH3b O12/O2 3-097/O12O2 
1c 3-097/1c Weak + Weak +  +  1-161
VDJ8 D3-22/D21-9 JH4b L11 3-098/L11 Weak + 
VDJ9 D2-8/DLR1 JH2 L8 3–099/L8
L2 3-099/L2
VDJ10 D1-14/DM2 JH6b O18/O8 3-0910/O18O8
VH3-07 VDJ11 D3-10/DXP’1 JH4b 1e 3-07/1e + +   Weak+5 1-161
VH3-30 VDJ12 D5-24 JH4b 3h 3-30/3h + +   + 1-161
Dsg1, desmoglein 1; Dsg1 epitope, amino-acid numbers in Dsg1; IB, immunoblot; IIF, indirect immunofluorescence.
1Each VDJ recombinatory region is defined by a CDR3 (the third complimentary-determining region) amino-acid sequence. Because of extensive diversity in
VDJ gene rearrangements, clones sharing identical VDJ sequences are considered to have arisen from the same B-cell clones.
2Intradermal injection into human foreskin grafted SCID mice (Berking et al., 2001) was used to test pathogenicity for this clone.
3One clone with unique light-chain VJ junction also stained epidermal basement membrane.
4Showed cytoplasmic staining.
5One clone with unique 1e VJ junction was negative.
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lines in Figure 1). The VH1-08 and VH3-07 clones showed
much weaker binding, and the VH3-30 clone showed
intermediate binding (Figure 1).
Indirect immunofluorescence on mouse tail and human skin.
All VH1-18 clones stained the cell surface of keratinocytes
throughout the human epidermis, stronger in the more super-
ficial epidermis, and identical to staining reported with PF
serum (Table 1; Amagai et al., 1996; Shirakata et al., 1998).
This pattern was also seen when antibodies were injected
into human skin organ culture (Figure 5b). These VH1-18
antibodies did not stain mouse skin. In contrast, VH3-09
antibodies stained the cell surface of human keratinocytes
weakly, if at all, and also did not bind well to mouse skin.
There was a suggestion of some cytoplasmic staining of
human epidermis with some of these VH3-09 antibodies,
most marked with 3-094/O18O8 (Figure 2). The VH3-07 and
VH3-30 clones strongly stained the cell surface of both
human and mouse epidermis (3-30/3h shown in Figure 2;
also see Figure 5). The staining with 3-30/3h was eliminated
when the human skin was preincubated with EDTA (Figure 2),
suggesting that the antibody binds a calcium-sensitive
epitope.
Binding to denatured Dsg1 and to unprocessed Dsg1
proprotein. VH1-18 clones bound denatured Dsg1 on
immunoblots unlike any of the other clones tested (Table 1
and Figure 3a). Interestingly, in immunoprecipitation experi-
ments using recombinant human Dsg1 produced by a
baculovirus expression system, clones 3-094/O18O8 and
3-097/1c immunoprecipitated a Dsg1 polypeptide with a
slightly greater apparent molecular weight on SDS-PAGE
than other clones (Figure 3b). As it is known that the insect
cells transfected with the recombinant baculovirus produce
both the proprotein and mature protein forms of Dsg1
(Hanakawa et al., 2002), this finding suggests that they bind
to the proprotein but not to the mature protein. Binding to
the proprotein is consistent with the cytoplasmic staining
seen by indirect immunofluorescence (Figure 2), because the
proprotein is believed to be processed to the mature form as
it reaches the cell surface (Wahl III et al., 2003).
Binding of Dsg4. Some pemphigus sera bind Dsg4 (Kljuic
et al., 2003; Nagasaka et al., 2004), and this binding is
thought to be due to antibodies against Dsg1 that crossreact
with Dsg4. To determine whether any of our anti-Dsg1 mAbs
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Figure 1. Binding curves of representative scFv antibodies against human
Dsg1 by ELISA. Serial dilutions of representative scFvs were measured
by Dsg1 ELISA. Clones 1-18/L1 and 1-18/L12 (light green lines) and
3-094/O18O8 and 3-097/1c (dark green lines) show similar binding curves.
In contrast, clones 1-08/O12O2 and 3-07/1e showed weak binding to
Dsg1 ELISA. Clone 3-30/3h exhibited intermediate binding capacity.
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3–30/3h (EDTA)
Figure 2. Indirect immunofluorescence of anti-Dsg1 scFvs on human skin.
Clone 3-30/3h scFv antibodies stained the cell surface of keratinocytes
throughout the human epidermis. Pretreatment of human skin with EDTA
prevented cell surface staining by 3-30/3h. Clone 3-094/O18O8 showed
cytoplasmic staining in the superficial layers of the epidermis.
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Figure 3. Binding of anti-Dsg1 scFvs to denatured Dsg1 and to Dsg4.
(a) The purified ectodomain of human Dsg1 with an E-tag (Dsg1-EHis),
produced by baculovirus, was used as an immunoblot substrate. ScFv
heavy-chain variable regions encoded by the gene VH1-18, but not other
scFvs, bound denatured Dsg1 on immunoblots. (b) Recombinant human
Dsg1 or Dsg4 containing an E-tag (Dsg1-EHis or Dsg4-EHis), produced by
baculovirus, was immunoprecipitated with representative anti-Dsg1 scFvs,
control scFv (AM3-13), or Talon metal affinity resin (Ni-beads) and
detected on an immunoblot by anti-E tag antibody.
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crossreact with Dsg4, we used scFvs to immunoprecipitate
recombinant Dsg4 containing a C-terminal E-epitope tag
(Nagasaka et al., 2004), and then identified its presence on an
immunoblot stained with anti-E tag antibodies. VH1-18,
VH3-07, and VH3-30 antibodies did not bind Dsg4, whereas
VH1-08 and VH3-09 antibodies did (Table 1 and Figure 3b).
Epitope mapping of anti-Dsg1 antibodies.We used a series of
four Dsg1/Dsg3 chimeric molecules to perform competition
assays with our various anti-Dsg1 scFvs (Futei et al., 2000).
As shown in Figure 4, VH1-18 clones bound to amino acid
nos. 164–401, whereas all others mapped to the N terminus
of Dsg1 (amino acid nos. 1–161) (Table 1).
Summary of immunochemical data. These data show that,
in general, the properties of our isolated antibodies correlate
with heavy-chain gene usage, even if the light chains are
encoded by a diversity of variable region genes. Overall,
the heavy chains of our anti-Dsg1 clones were encoded by
only five different heavy-chain genes belonging to only
two heavy-chain gene families (VH1 and VH3), whereas
light-chain gene usage was significantly more promiscuous.
Light-chain shuffling shows that only certain light chains can
pair with the restricted heavy chains to allow Dsg1 binding
Although the heavy-chain gene usage is generally associated
with the immunochemical properties of these scFvs, and the
light-chain gene usage is much less restricted, light-chain
shuffling experiments show that the pairing of light and heavy
chains is not entirely random, as only certain light chains
allow binding to Dsg1. To demonstrate the light-chain
contribution to Dsg1 binding, we constructed a derivative
phage display library using the heavy chain of scFv 3-098/L11
paired with the entire original light-chain repertoire from the
PF patient. Analysis of 16 clones from this derivative library
before panning showed that none bound to Dsg1 by ELISA,
even though all had the VH3-09 heavy chain. The clones did,
however, bind an anti-hemagglutinin (HA) tag-coated ELISA
plate, showing that the scFv (which is engineered to express
the HA tag on its C terminus) was expressed on the phage
surfaces. However, when this library was panned against
Dsg1 to select anti-Dsg1 clones, these clones used the L11,
A30, or 1c light-chain genes, as were found in the anti-Dsg1
clones isolated from the original libraries. These data suggest
that only certain light chains permit Dsg1 binding when
paired to this heavy chain.
A monoclonal anti-Dsg1 scFv can cause the pathology of PF
Initially, we tested for pathogenicity in the neonatal mouse
model of pemphigus. Because VH1-18 and VH3-09 clones
did not bind well to mouse skin by indirect immunofluore-
scence, we did not expect them to bind epidermis or induce
pathology, which turned out to be the case (Table 1).
However, clones 1-08/O12O2 and 3-07/1e did not induce
pathology either, even though they did bind mouse epidermis
(Figure 5a). Clone 3-30/3h, however, caused extensive gross
blisters with the typical histology and direct immunofluores-
cence of PF (Figure 5a).
Given the possibility that some monoclonal anti-Dsg1
antibodies might be specific for human rather than mouse
pathogenic epitopes, we tested representative scFv clones by
injecting them into freshly isolated human skin biopsies, which
were then maintained in organ culture for 24 hours. Immuno-
fluorescence of these cultures showed binding of antibodies to
the epidermal cell surface (except for VH3-09 antibodies,
consistent with their weak binding to the keratinocyte
cytoplasm by indirect immunofluorescence), but only 3-30/
3h caused extensive histologic blisters (detaching essentially
the whole stratum corneum) with features typical of PF,
whereas 3-07/1e caused focal blisters (with areas of stratum
corneum still attached) with typical histology (Figure 5b).
These findings demonstrate that an anti-Dsg1monoclonal
(and monovalent) antibody that does not bind to Dsg4 can
cause the pathology of PF. In addition, one clone (3-07/1e)
was specific for a human pathogenic epitope not shared in
the mouse, but one clone (3-30/3h) caused disease in both
humans and mice.
A common pathologic epitope on Dsg1, defined by scFv 3-30/
3h, is targeted by multiple PF sera and PV sera that contain
anti-Dsg1 antibodies
ELISA inhibition studies, in which patients’ sera were used to
inhibit the binding of scFv to Dsg1, were used to determine if
antibodies from various patients bind at or near the epitopes
bound by the scFv (Table 2). Most strikingly, clone 3-30/3h,
the most pathogenic scFv, was inhibited by 6/6 PF sera and 5/
5 PV sera that contain both anti-Dsg3 and anti-Dsg1
antibodies but none of the three PV sera that contain only
Dsg1-lghis
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Figure 4. Epitope mapping with competition ELISA. Wild-type and domain-swapped extracellular domains of human Dsg1 and Dsg3 were produced
by baculovirus and used as competitors in ELISA as described in the Materials and Methods section. The molecular structure of domain-swapped
molecules is shown. ‘‘þ ,’’ greater than 40% inhibition.
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anti-Dsg3 antibodies (Figure 6a). It is known that in
mucocutaneous PV, the anti-Dsg1 antibodies are pathogenic
(Ding et al., 1999). These results suggest that the pathogenic
anti-Dsg1 antibodies in PF and mucocutaneous PV sera
inhibit epitopes identical or similar to those defined by scFv
3-30/3h, suggesting that this clone defines an important
epitope on Dsg1 that is targeted to cause pathology in many,
if not all, PF and mucocutaneous PV patients.
Other anti-Dsg1 clones were inhibited in their binding to
Dsg1 by fewer PF and PV patients’ sera, suggesting that the
epitopes defined by these clones were not as well preserved
among patients as was that defined by clone 3-30/3h.
Epitopes defined by scFvs isolated from one PF patient comprise
major targets of the autoantibody response in other PF patients
A mixture of non-pathogenic and pathogenic scFvs derived
from PF patient 1 was tested for its ability to block the binding
Table 2. Inhibition of anti-Dsg1 scFv binding by
pemphigus sera in ELISA
scFv
VH VL PF sera PV (3+1) sera1 PV (3) sera
1-18 L1 2/62 0/5 0/3
1-18 L12 1/6 0/5 0/3
1-08 O12/O2 4/6 3/5 0/3
3-094 O18/O8 4/6 0/5 0/3
3-095 O18/O8 4/6 2/5 0/3
3-097 1c 4/6 2/5 0/3
3-07 1e 3/6 0/5 0/3
3-30 3h 6/6 5/5 0/3
Dsg1, desmoglein 1; PF, pemphigus foliaceus; PV, pemphigus vulgaris;
scFv, single-chain variable fragment.
1PV(3+1) sera indicate PV sera containing anti-Dsg3 and anti-Dsg1
antibodies, whereas PV(3) sera means PV sera containing only anti-Dsg3
antibody.
2The number of sera that inhibit/the number of sera tested.
1-08/O1202
1-08/O12021-18/L12
3-07/1e
3-07/1e3-094/O1808
3-30/3h
3-30/3hb
Figure 5. A monovalent monoclonal anti-Dsg1 scFv causes typical PF blister
formation in neonatal mice and human skin. (a) Passive transfer of anti-Dsg1
scFvs into neonatal mice. Images were taken 6 hours after subcutaneous
injection of scFvs. The gross appearance of the mice, and their skin histology
and direct immunofluorescence are shown. Injection of 3-30/3h scFv caused
gross blisters on the back (arrow), due to blistering in the granular layer of
the epidermis. Direct immunofluorescence showed binding of these scFvs to
the cell surface of the mouse epidermis (brackets indicate stratum corneum).
(b) Pathogenicity assay using human skin. Anti-Dsg1 scFvs were injected
into human skin specimens that were then cultured for 24 hours. Histology
and direct immunofluorescence of the skin are shown. All scFvs, except
3-94/O18O8, bound to the cell surface of epidermal keratinocytes. 3-7/1e
and 3-30/3h caused PF-like superficial epidermal blisters.
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Figure 6. Multiple pemphigus sera target the same or nearby epitopes
defined by anti-Dsg1 scFvs. (a) Six PF sera, five mucocutaneous PV sera
containing Dsg1 and Dsg3 antibodies (PV(3þ 1)), three mucosal PV sera
containing only Dsg3 antibody (PV (3)), and a normal control serum (N) were
used to block the binding of pathogenic scFv clone 3-30/3h to Dsg1.
All PF sera and all PV(3þ1) sera tested inhibit the binding of 3-30/3h.
(b) The binding of PF sera to Dsg1 was blocked by poly scFvs P3 (a mixture
of scFvs derived from clones that bind Dsg1 after three rounds of routine
pannings, and which contain almost all non-pathogenic scFvs as shown from
previous characterization of these clones), pathogenic scFvs (3-07/1e and
3-30/3h), or a combination of poly scFvs P3 and pathogenic scFvs. Serum
from PF patient 1 from which the phage library was made (PF1-nlib) and four
other PF sera were tested. These results show that the scFv isolated by phage
display from PF patient 1 block most epitopes bound by other PF sera and
that other PF sera bind the epitopes (or nearby epitopes) defined by the
two pathogenic clones. Clones 3-07 and 3-30 provide most of the inhibition
of PF sera but are minor components of the poly scFv from the third
panning (P3), which alone does not inhibit well most of the PF sera.
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of various PF patient sera to Dsg1. As shown in Figure 6b, the
mixture blocks490% of Dsg1 binding by the serum from the
patient from whom the antibody phage display library was
constructed (PF1-lib). This suggests that the isolated scFvs
identify nearly all epitopes targeted by serum IgG from PF
patient 1. In addition, this combination of scFvs blocks
70–100% of Dsg1 binding in four other randomly selected PF
patient sera.
Furthermore, significant antibody responses against patho-
genic epitopes are found across patients as evidenced by the
ability of the two pathogenic scFv clones, 3-30/3h and 3-07/
1e, to identify major pathogenic epitopes to which antibodies
in many other PF sera bind closely. These two scFvs alone
block 60% of binding of the serum from PF patient 1; 3-30/3h
alone, the most pathogenic antibody, blocks this serum
binding by almost 50%. The combination of 3-30/3h and
3-07/1e block the binding of unrelated PF patients’ sera
by 46–83%, showing that the epitopes defined by these
two scFvs are likely involved in many PF patients, and
antibodies that bind to them (or nearby) are a major part of
the autoantibody response in PF sera.
DISCUSSION
Utilizing antibody phage display and conventional library
panning on Dsg1 isolated only non-pathogenic scFv mAbs
from a PF patient. Clones that were repeatedly isolated
were encoded by only two heavy chain genes (VH1-18
and VH3-09), although there was a greater diversity in
the genetic origin of their light chains (Table 1). By blocking
the epitopes defined by these non-pathogenic antibodies with
a set of scFvs using these two VH genes, two additional
clones were isolated that used distinct heavy-chain genes
(VH3-30 and VH3-07) and were pathogenic. These clones
show that a single monovalent, monoclonal anti-Dsg1
antibody can cause the formation of blisters that typify PF.
Inhibition ELISA studies using these pathogenic scFv mAbs
with multiple PF sera suggest that the pathogenic antibody
response among patients with PF is limited and directed at
similar or identical epitopes on Dsg1. These epitopes are
located in the N terminus of Dsg1, an area that includes
the transadhesive interface that has been shown to be a target
for pathogenic anti-Dsg3 antibodies in PV (Tsunoda et al.,
2003). In addition, the epitopes are conformational and
calcium-stabilized, similar to pathologic Dsg3 epitopes in PV
(Payne et al., 2005).
Analysis of the non-pathogenic and pathogenic clones that
we isolated showed that their immunological properties
correlated mostly with their heavy-chain gene usage.
Very restricted heavy-chain gene usage, limited to only five
genes, characterized the anti-Dsg1 antibodies. Although the
light-chain gene usage was more promiscuous, light-chain
shuffling experiments showed that only certain light chains
were permissive for Dsg1 binding. Our findings also suggest
that some antibodies may bind the proprotein of Dsg1
and not the mature protein. If so, patients may have a
response against intracellular Dsg1 before it is completely
processed. These latter findings suggest the intriguing
possibility that PF patients might first develop antibodies
against the intracellular proprotein to which they would not
be expected to have tolerance, and in some susceptible
patients the antibody response might extend to the mature
molecule through epitope spreading.
Epitope blocking has been used with phage display in
other contexts, for example, in finding neutralizing human
mAbs against HIV-1 and respiratory synticial virus (Ditzel
et al., 1995; Tsui et al., 2002). In our case, the use of blocking
to mask non-pathogenic epitopes resulted in finding patho-
genic antibodies that represented a major autoantibody
response in various PF patients. This approach could be
applied to other autoantibody-mediated diseases when
routine panning might not be adequate.
Interestingly, VH3-30 gene usage, which defines the major
pathologic antibody found here, has also been documented
in other autoantibody-mediated diseases, such as auto-
immune hemolytic anemia, idiopathic thrombocytopenic
purpura, and system lupus erythematosus (Efremov et al.,
1996; Roben et al., 1996; Roark et al., 2002).
We previously isolated human anti-Dsg3 mAbs from a
PV patient (Payne et al., 2005). Interestingly, some of the
anti-Dsg3 antibodies share heavy-chain gene usage with
our pathogenic anti-Dsg1 antibodies. For example, the
pathogenic anti-Dsg3 antibody (D3)3c/9 was derived from
VH3-07, as was one of the two pathogenic anti-Dsg1
antibodies from the PF phage library. Furthermore, this
pathogenic anti-Dsg3 antibody, D(3)3c/9, reacted with both
Dsg3 and Dsg1 (although weakly to the latter). Similarly, the
pathogenic anti-Dsg1 scFv 3-07/1e also bound weakly to
Dsg3. Further studies will be necessary to determine how
common-shared heavy-chain gene usage is in the pathogenic
antibodies from other PV and PF patients.
The findings presented here may have diagnostic and
therapeutic implications for PF. For example, if the repertoire
of pathogenic antibodies and their idiotypes are limited or are
encoded by the same heavy-chain genes across patients,
more targeted therapy might be possible (Payne et al., 2007).
For example, if VH3-30 gene usage for the most pathogenic
antibodies in PF is generalizable to most patients, then
the infusion of Staphylococcal protein A might be used to
inactivate B cells expressing those genes through a B-cell
antigen receptor-induced apoptotic event as described in
murine models (Graille et al., 2000; Goodyear and Silver-
man, 2003; Silverman and Goodyear, 2006) and as suggested
for other autoimmune patients treated by extracorporeal
protein A immunoabsorption (Silverman et al., 2005).
Another practical implication of our findings is that it may
be possible to design ‘‘pathogenic antibody ELISAs’’ by
blocking non-pathogenic Dsg1 epitopes with non-pathogenic
scFvs, and then measuring anti-Dsg1 serum titers. Alterna-
tively, inhibition by PF sera of binding of pathogenic scFvs to
Dsg1 could be determined. It might then become feasible
to determine if there is less pathogenic antibody (at least
to these two major epitopes defined here) when patients are
in remission and increased pathogenic antibody with more
active disease.
In conclusion, we have isolated and characterized the
first set of human mAbs against Dsg1 from a PF patient and
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have shown that a monoclonal human scFv can disrupt the
function of Dsg1 and cause blistering typical of PF. The two
pathologic scFvs from this patient define epitopes that are
targets of a major antibody response in this and other PF
patients. Finally, these reagents will be useful for under-
standing the molecular mechanism of blister formation in PF,
the function of Dsg1 in adhesion, and may lead to targeted
therapy and more accurate diagnostic tools for this severe
blistering disease.
MATERIALS AND METHODS
Construction of phage library
Using previously described methods (Barbas III et al., 2001), we
constructed separate IgG-k and IgG-l phage libraries from 1 107
mononuclear cells isolated from 50ml of peripheral blood collected
from a PF patient, a 76-year-old Caucasian woman with clinically
active disease (involving approximately 30% of her body area) for 1
year in spite of being on prednisone 60mg q.d. Briefly, reverse
transcriptase-PCR was used to amplify the immunoglobulin variable
regions of the heavy (VH) and light chains (VL), and the gene
fragments were then cloned into the phagemid vector pComb3X
(Scripps Institute, La Jolla, CA). The phagemid library was electro-
polated into XL-1 Blue suppressor strain of E. coli (Stratagene,
La Jolla, CA) with superinfection by VCSM13 helper phage (Stratagene).
In this system, filamentous phage particles express scFv antibodies
(with a C-terminal 6 histidine tag and a HA tag) fused to the pIII
bacteriophage coat protein. Recombinant phages were purified from
culture supernatants by polyethylene glycol precipitation and
resuspended in phosphate-buffered saline, pH 7.4 with 1% BSA
containing1mM CaCl2. The library comprised more than 2 108
independent transformants as determined by titering on E. coli XL1-
Blue after transformation. To validate library diversity, we analyzed
the sequences of 14 phage clones from the unpanned library. We
found no duplicate sequences and marked heterogeneity in VH and
VL gene usage, similar to that found in normal human peripheral
blood lymphocytes (data not shown).
Panning of phage library
Phage selection against Dsg1 absorbed to a solid phase.
ELISA plates coated with recombinant Dsg1 (MBL, Nagoya, Japan)
were used to isolate phage clones that express anti-Dsg1 scFv as
described previously (Payne et al., 2005). Briefly, four wells were
incubated with blocking buffer (50mM Tris pH 7.5, 150mM NaCl,
1mM CaCl2[TBS-Ca] with 3% skim milk) at room temperature for
1 hour. The phage library was diluted into blocking buffer and then
incubated with Dsg1 on the wells for 2 hours at room temperature.
After 5–10 washes with TBS-Ca containing 0.1% Tween 20, adherent
phages were eluted with 76mM citric acid, pH 2.0, incubated for
10minutes at room temperature and then neutralized with 2M
unbuffered Tris. The eluted phages were amplified in XL1-Blue
E. coli and rescued by superinfection with VCSM13 helper phage.
Phages were harvested from bacterial culture supernatant and then re-
panned against Dsg1 ELISA plates for three additional rounds.
Individual phage clones were isolated from each round of panning
and then analyzed for binding to Dsg1 by ELISA using horseradish
peroxidase (HRP)-conjugated anti-M13 antibody (GE Healthcare Bio-
Sciences, Uppsala, Sweden). For epitope-blocked panning, the phage
library was first mixed with purified recombinant non-pathogenic scFvs
(clones 1-18/L1, 1-18/L12, 3-094/O18O8, and 3-093/O12O2) and then
incubated on immobilized Dsg1 for 2hours at room temperature.
Phage selection against mammalian-produced Dsg1 in
solution. cDNA encoding the extracellular region of human Dsg1
fused with the Fc portion of human IgG1 and a histidine tag (six
histidine residues) (Dsg1-IgHis) was subcloned into pcDNA3-1
(Invitrogen, Carlsbad, CA). The resultant construct was transiently
transfected into 293T cells using jet PEI (Polyplus-transfection Inc.,
New York, NY). The recombinant protein was purified from the
culture supernatant with Talon metal affinity resin according to
the manufacturer’s protocol (Clontech Laboratories Inc., Mountain
View, CA).
The PF patient antibody phage library (2 1011CFU (colony-
forming units)) was precleared by incubation with the Fc fragment of
human IgG (Jackson ImmunoResearch Laboratories Inc., West
Grove, PA), which was then removed by protein G magnetic beads
(New England Biolabs, Ipswich, MA). The precleared phage library
was then incubated with recombinant Dsg1-IgHis at room tempera-
ture for 20minutes. Phages bound to Dsg1-IgHis were captured
by protein G magnetic beads, washed with Tris-buffered saline
containing 0.1% Tween 20, then eluted with 0.2 M glycine-HCl,
pH 2.2 and immediately neutralized with 1M Tris–HCl, pH 9.1.
Eluted phages were amplified in XL1-Blue E. coli, followed by
superinfection with helper phage as described above. Phages were
harvested from bacterial culture supernatant and re-panned against
Dsg1-IgHis in solution. Protein G magnetic beads and protein A
magnetic beads (New England Biolabs) were used in alternate
rounds of panning to avoid isolation of phage that bound non-
specifically to protein A or G.
Sequence analysis of scFv antibodies
Recombinant phagemids were purified with a plasmid preparation
system (Qiagen, Valencia, CA), and the VH and VL inserts were
sequenced using pComb3X-specific primers described previously
(Barbas III et al., 2001). The nucleotide sequences were compared
with the germline sequences in V Base sequence directory (http://
vbase.mrc-cpe.cam.ac.uk/) to determine their germline gene origins
and interrelatedness.
Production and purification of soluble scFvs
The Top10 F’ non-suppressor strain of E. coli (Invitrogen Corp.,
Carlsbad, CA) was infected with an individual phage clone, and
soluble scFvs were purified from the bacterial periplasmic space
using sucrose shock or Fastbeak (Promega, Madison, WI) and Talon
metal affinity resin (Clontech Laboratories Inc.) as described
previously (Payne et al., 2005).
Dsg1 and Dsg3 scFv ELISA
The reactivity of scFv against human Dsg1 and Dsg3 was measured
by Dsg1 and Dsg3 ELISA (MBL) using HRP-conjugated anti-HA mAb
(clone 3F10, 1:1,000 dilution; Roche Diagnostics Corp., Basel,
Switzerland) as a secondary antibody as described (Payne et al.,
2005).
Inhibition ELISA
Inhibition of scFv binding by pemphigus sera. Inhibition ELISA
to block the binding of scFv to Dsg1 by pemphigus sera was
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performed as described previously for PV mAbs (Payne et al., 2005).
Briefly, scFvs were used at dilutions that resulted in an OD450
reading of approximately 1.0 in the Dsg1 ELISA in the absence of
blocking serum. The diluted scFv, mixed with pemphigus or normal
control sera (10ml), was analyzed by Dsg1 ELISA developed with
HRP-conjugate anti-HA antibody. Inhibition was calculated accord-
ing to the following formula: % inhibition¼ [1(ODS/B–ODSc/B)/
(ODS/BcODSc/Bc)] 100, where S is the scFv being tested, Sc the
scFv-negative control, B the blocking pemphigus serum, and Bc the
normal human serum.
Inhibition of PF sera binding by scFvs. PF sera were diluted to
result in an OD450 reading of approximately 1.0 in the Dsg1 ELISA
without competitors. The diluted PF sera, mixed with scFvs, were
analyzed by Dsg1 ELISA developed with HRP-conjugate anti-human
Fab antibody. Inhibition was calculated according to the following
formula: % inhibition¼ [1(ODT/BODN/B)/(ODT/Bc–ODN/
Bc)] 100, where T is the PF sera tested, N the normal control
serum, B the blocking monoclonal anti-Dsg1 scFvs, and Bc the
control scFv (AM3-13).
Epitope mapping by competition ELISA
Extracellular, domain-swapped Dsg1 and Dsg3 recombinant mole-
cules were produced by a baculovirus expression system as
described previously (Futei et al., 2000). ScFvs were diluted so that
Dsg1 ELISA readings at OD450 were approximately 1.0 in the
absence of a competitor. The diluted scFvs were incubated with an
excess amount of baculovirus culture supernatant containing the
recombinant proteins for 30minutes at room temperature. Immuno-
blot analysis confirmed that each culture supernatant contained
approximately the same amount of recombinant protein (data not
shown). The mixture was subjected to Dsg1 ELISA (MBL) developed
with HRP-anti-HA antibody. Inhibition was calculated using the
following formula: inhibition (%)¼ [1(OD competitor–OD blank)/
(OD-negative–OD blank)] 100, where OD competitor is an OD
obtained with scFv incubated with culture supernatant with a
recombinant baculoprotein; OD-negative is an OD obtained with
sera incubated with culture supernatant of uninfected High Five
insect cells; OD blank is an OD obtained with secondary antibody
only. Greater than 40% inhibition was considered positive.
Direct and indirect immunofluorescence
Immunofluorescence for scFvs was performed on human skin,
mouse tail, or neonatal mouse skin as described previously (Payne
et al., 2005). Binding was detected with rat monoclonal anti-HA
antibody (3F10, 1:100 dilution; Roche Diagnostics) followed by
Alexa Fluor 568-conjugated anti-rat IgG (1:200 dilution; Invitrogen).
Immunoblotting
The ectodomain of human Dsg1 tagged with an E-tag and a histidine
tag (Dsg1-EHis), produced by a baculovirus expression system,
was used as substrate (Ishii et al., 1997). The recombinant
proteins were size fractionated by SDS-PAGE and transferred to
nitrocellulose membranes. The membranes were incubated with
scFvs diluted in phosphate-buffered saline/5% milk, followed
by HRP-conjugated anti-HA antibody (1:1,000 dilution; Roche
Diagnostics) and developed by ECL plus reagent (GE Healthcare
Bio-Sciences).
Immunoprecipitation–immunoblotting analysis for Dsg4
binding
To determine whether anti-Dsg1 scFvs also bind Dsg4, we used
baculovirus-produced recombinant human Dsg4-EHis and human
Dsg1-EHis (‘‘EHis’’ tag defined above) (Nagasaka et al., 2004).
Baculovirus-infected insect cell culture supernatants containing
recombinant molecules were incubated with scFvs for 30minutes
and then immunoprecipitated with anti-HA agarose (Sigma-Aldrich,
St Louis, MO) at 41C for 2 hours with gentle rotation. After washing
with TBS-Ca, the immunoprecipitates were resuspended in Laemmli
sample buffer, separated by SDS-PAGE and then transferred to
nitrocellulose membranes (Bio-Rad Laboratories, Hercules, CA).
Membranes were probed with HRP-conjugated anti-E-tag antibody
(1:2,000 dilution; GE Healthcare Bio-Sciences).
Neonatal mouse injection
Purified scFv (100ml) were injected subcutaneously along the back
into 1- to 2-day-old neonatal C57Bl/6J mice. The mice were killed at
6 hours, and the skin was harvested for direct immunofluorescence
and for histology. All mouse studies were approved by the University
of Pennsylvania IACUC Committee.
Human skin organ culture injection
Specimens were obtained from leftover normal skin after excisional
surgery. The specimens were trimmed by removing fat tissue and cut into
5-mm diameter pieces. After an intradermal injection of 50ml of purified
scFv using an insulin syringe, skin specimens were put on the insert of
transwells (Corning, NY) with defined keratinocyte SFM (Invitrogen)
containing 1.2mM CaCl2 in the outer compartment. At 24hours, the skin
was harvested for direct immunofluorescence and for histology.
Institutional review board approvals
All studies involving mice, human blood, and skin were approved by
the appropriate University of Pennsylvania Institutional Review Board.
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